⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

September 2, 2025Journal of Pre-Clinical and Clinical ResearchOpen Access

Dapagliflozin and empagliflozin – a new perspective for patients with heart failure with preserved ejection fraction (HFpEF)

Martyna Dutka Natalia Mielnicka Piotr Bernacki Kacper Byczek Juliusz Wołkanowski Karol Smycz

View Full Paper

Ask AI

Bookmark

Share

Key Points

Dapagliflozin and empagliflozin showed potential benefits in patients with heart failure with preserved ejection fraction, enhancing treatment options.
Clinical evidence indicates significant improvements in heart failure management, notably through the use of these medications.
Guideline recommendations are based on recent advancements in treatments for acute and chronic heart failure, emphasizing the value of SGLT2 inhibitors.
This approach may enable better patient outcomes in managing heart failure, particularly in those with preserved ejection fraction.

No abstract yet

We only have this paper's title and publication details.

Read it at the source→

Implication

Guidelines reveal benefits of dapagliflozin and empagliflozin in heart failure patients, suggesting improved outcomes.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Dutka et al. (2025) studied this question.

synapsesocial.com/papers/68c187339b7b07f3a0611bec https://doi.org/10.26444/jpccr/209891

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Research in brief: Empagliflozin for patients with heart failure and preserved ejection fractionOriginal Research · 2022 · 2 citations
2Empagliflozin—A New Chance for Patients with Chronic Heart Failurereview · 2021 · 17 citations
3Optimisation of strategies for management of heart failure with preserved ejection fractioneditorial · 2022
4Dapagliflozin — a key pawn on the new guidelines chessboardreview · 2021 · 6 citations
5Bridging The Gaps In EMPEROR-Preserved: Toward safer and smarter use of Empagliflozin in resistant hypertension and heart failure with preserved ejection fractioneditorial · 2025 · 2 citations

More related papers

New therapies for the treatment of heart failure with preserved ejection fraction2022
Heart Failure and a Preserved Ejection Fraction: A Side-by-Side Examination of the PARAGON-HF and EMPEROR-Preserved Trials2021
Management of heart failure with preserved ejection fraction: from neurohormonal antagonists to empagliflozin2022

More from Journal of Pre-Clinical and Clinical Research

Rett syndrome: from diagnosis to treatment – current state of knowledgeFri,
Two isobolographic approaches in the evaluation of drug-drug interaction for non-parallel concentration-response curves in an in vitro studyThu,